Navigation Links
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Date:1/5/2009

d trial and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
(Date:7/30/2015)... ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor management ... over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... world to tiny robots demonstrating soccer skills are ... to advance microroboticsthe field devoted to the construction ... measured in micrometers (millionths of a meter). ... in collaboration with IEEE, is inviting university and ...
... 2009 -- Taking nanomaterials to a new level of ... into arrow-straight nanowires, transforming them into zigzagging two- and ... is described this week in the journal Nature ... Tian and Charles M. Lieber. Among other ...
... , PHILADELPHIA, Oct. 21 ERT (Nasdaq: ERES ), ... other services to the biopharmaceutical, medical device, and related industries, ... 2009 third quarter on Thursday, October 29, 2009 after the ... conference call at 5:00 PM EDT that day. , ...
Cached Biology Technology:Is your microrobot up for the (NIST) challenge? 2Harvard scientists bend nanowires into 2-D and 3-D structures 2ERT to Announce 2009 Third Quarter Results on October 29, 2009 2
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... Recent experiments conducted at the Australian Institute of ... first time that corals hosting a single type of ... a feature that was only known previously for corals ... cells that live within the tissue of living coral ...
... chemically unique environment, which at first glance appears hostile to ... the earth, through which water flows, laden with volcanic gases ... is precisely this extreme environment, where the two mechanisms could ... The multiplication of biomolecules (reproduction) and the emergence of new ...
... noses, but a huge part of their brains is dedicated ... smell more than any other sense for essential activities such ... discovered that a gene called distal-less is critical to the ... As reported in the current issue of the Proceedings ...
Cached Biology News:Multiple partners not the only way for corals to stay cool 2Avalanche of reactions at the origin of life 2Avalanche of reactions at the origin of life 3Researchers find gene critical to sense of smell in fruit fly 2Researchers find gene critical to sense of smell in fruit fly 3
ANTI S. GROUP AG:H...
Recorder REC-111 single-channel, 1. Category: Chromatography Systems & Accessories, Systems....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... WR Cryoscope for molecular weight determinations for petroleum-based applications. Multiple solvents can be used, such ... ... ... ...
Biology Products: